Etonogestrel

Summary

Etonogestrel (CHEMBL1531) is an approved small-molecule contraceptive drug (ATC G03AC08); indicated across 6 conditions including benign prostatic hyperplasia and aids.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: G03AC08
• Indications: 6 conditions
• Clinical trials: 32
• Chemistry: 324.5 Da · C22H28O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1531
Name	Etonogestrel
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	6917715
ChEBI	CHEBI:50777
ATC	G03AC08
Molecular formula	C22H28O2
Molecular weight	324.5
InChIKey	GCKFUYQCUCGESZ-BPIQYHPVSA-N

SMILES: CC[C@]12CC(=C)[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34

IUPAC name: (8S,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-11-methylidene-2,6,7,8,9,10,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one

Pharmacological roles (ChEBI): contraceptive drug, progestin, female contraceptive drug.

Also known as: Desogestrel related compound c, Etonogestrel, Etonogestrel component of nuvaring, Implanon, Nexplanon, ORG 3236, ORG-3236, ETONOGESTREL, SID144206191, etonogestrel, EtonogestrelÊ, EtonogestrelÂ

Patent coverage: 1,316 distinct patent families (4,893 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 6 (assay-derived). Sample: Androgen receptor, Estrogen receptor, Progesterone receptor, Mu-type opioid receptor, Sex hormone-binding globulin, Gamma-aminobutyric acid receptor subunit alpha-1.

Bioactivity

ChEMBL activities: 4 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
PGR	8.52	AC50	3	nM	CHEMBL_ACT_25204360
SHBG	8.23	Kd	5.89	nM	CHEMBL_ACT_2155711
AR	8.11	AC50	7.8	nM	CHEMBL_ACT_25203427
ESR1	5.25	AC50	5620	nM	CHEMBL_ACT_25138927

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

6 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
benign prostatic hyperplasia	2	MONDO:0010811	EFO:0000284
AIDS	2	MONDO:0012268	EFO:0000765
HIV infectious disease	2	MONDO:0005109	EFO:0000764
systemic lupus erythematosus	2	MONDO:0007915	MONDO:0007915

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 32.

Phase distribution

Phase	Trials
Not specified	14
PHASE4	11
PHASE2	3
PHASE3	1
PHASE2/PHASE3	1
PHASE1	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05237141	PHASE4	RECRUITING	Etonogestrel Implant as Emergency Contraception
NCT01388582	PHASE4	COMPLETED	The Effect of Hormonal Contraceptives on Breast-milk Production and Infant Growth
NCT01448291	PHASE4	UNKNOWN	Effect of the Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring on Vaginal Innate and Inflammatory Biomarkers
NCT01767285	PHASE4	COMPLETED	Immediate vs. Delayed Postpartum Etonogestrel Implant
NCT02082652	PHASE4	COMPLETED	A Pharmacokinetic Evaluation of Etonogestrel (ENG) Implant and Antiretroviral Therapy
NCT02480647	PHASE4	COMPLETED	Clinical Trial the Use of Levonorgestrel-releasing Intrauterine System Versus Etonogestrel Implant in Endometriosis
NCT03120728	PHASE4	UNKNOWN	Application for the Etonogestrel/Ethinyl Estradiol Ring
NCT03978598	PHASE4	COMPLETED	Breastfeeding Etonogestrel Implant Study
NCT04257500	PHASE4	COMPLETED	Does Vaginal Delivery of Combined Hormonal Contraception Affect the Risk of Metabolic Syndrome in Overweight/Obese Women With PCOS
NCT04463693	PHASE4	COMPLETED	Shoulder Contraceptive Implant Study
NCT04814927	PHASE4	COMPLETED	Impact of Contraceptives on Cervico-Vaginal Mucosa
NCT00620464	PHASE3	COMPLETED	A Bioequivalence Study of IMPLANON and Radiopaque IMPLANON (34528)(P05720)
NCT05791799	PHASE2/PHASE3	UNKNOWN	Etonogestrel Implants Protect Ovarian Reserve Function in Systemic Lupus Erythematosus
NCT00651807	PHASE2	TERMINATED	A Trial to Investigate the Effectiveness and Safety of Org 3236 (Etonogestrel) Tablets in Men With Urinary Complaints Suggestive of a Benign Enlargement of the Prostate (304001)(P05806)
NCT01709318	PHASE2	COMPLETED	A Dose-Finding Study to Evaluate Ovarian Function and Vaginal Bleeding in Next Generation Rings (P06109/MK-8175A/MK-8342B-012)
NCT03282799	PHASE2	COMPLETED	Pharmacologic Strategies for the Etonogestrel Implant in HIV-Infected Women
NCT05174884	PHASE1	ACTIVE_NOT_RECRUITING	Casea S Contraceptive Implants (Casea S) Trial
NCT05760144	EARLY_PHASE1	RECRUITING	Endometrial Biopsy in Progestin Contraceptive Users
NCT06936436	Not specified	NOT_YET_RECRUITING	the Effect of Implanon on Menstrual Patterns
NCT07509138	Not specified	NOT_YET_RECRUITING	Quality of Life in Women Using LARC Contraception
NCT00042289	Not specified	COMPLETED	Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
NCT00828542	Not specified	COMPLETED	Safety of the Etonogestrel-releasing Implant During the Puerperium of Healthy Women
NCT00931827	Not specified	COMPLETED	Acceptability of Long-term Progestin-only Contraception in Europe
NCT01356927	Not specified	COMPLETED	Same-day Long-acting Reversible Contraception for Medication Abortion
NCT01873170	Not specified	COMPLETED	Quantification of Immune Cells in Women Using Contraception (CHIC II)
NCT02267616	Not specified	COMPLETED	Effectiveness of Prolonged Use of IUD/Implant for Contraception
NCT02414919	Not specified	COMPLETED	Duration of Use of Highly Effective Reversible Contraception
NCT02579590	Not specified	COMPLETED	The Female Sexual Functions With Progestogen-only Contraception
NCT03058978	Not specified	COMPLETED	Assessing Ovarian Function During Prolonged Implant Use
NCT03398811	Not specified	COMPLETED	Abnormal Uterine Bleeding and Progestin-only Contraceptives
NCT05742503	Not specified	COMPLETED	Progesterone Containing Contraceptive Methods on Endogenous Progesterone Level
NCT06378489	Not specified	UNKNOWN	The Use of Etonogestrel Contraceptive Implant as Treatment for Endometrial Hyperplasia Without Atypia: A Cohort Study

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).